FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136455060> ?p ?o ?g. }

• W3136455060 abstract "Abstract Background CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2) is an ultra-rare, neurodegenerative lysosomal storage disease, caused by an enzyme deficiency of tripeptidyl peptidase 1 (TPP1). Lack of disease awareness and the non-specificity of presenting symptoms often leads to delayed diagnosis. These guidelines provide robust evidence-based, expert-agreed recommendations on the risks/benefits of disease-modifying treatments and the medical interventions used to manage this condition. Methods An expert mapping tool process was developed ranking multidisciplinary professionals, with knowledge of CLN2 disease, diagnostic or management experience of CLN2 disease, or family support professionals. Individuals were sequentially approached to identify two chairs, ensuring that the process was transparent and unbiased. A systematic literature review of published evidence using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance was independently and simultaneously conducted to develop key statements based upon the strength of the publications. Clinical care statements formed the basis of an international modified Delphi consensus determination process using the virtual meeting (Within3) online platform which requested experts to agree or disagree with any changes. Statements reaching the consensus mark became the guiding statements within this manuscript, which were subsequently assessed against the Appraisal of Guidelines for Research and Evaluation (AGREEII) criteria. Results Twenty-one international experts from 7 different specialities, including a patient advocate, were identified. Fifty-three guideline statements were developed covering 13 domains: General Description and Statements, Diagnostics, Clinical Recommendations and Management, Assessments, Interventions and Treatment, Additional Care Considerations, Social Care Considerations, Pain Management, Epilepsy / Seizures, Nutritional Care Interventions, Respiratory Health, Sleep and Rest, and End of Life Care. Consensus was reached after a single round of voting, with one exception which was revised, and agreed by 100% of the SC and achieved 80% consensus in the second voting round. The overall AGREE II assessment score obtained for the development of the guidelines was 5.7 (where 1 represents the lowest quality, and 7 represents the highest quality). Conclusion This program provides robust evidence- and consensus-driven guidelines that can be used by all healthcare professionals involved in the management of patients with CLN2 disease and other neurodegenerative disorders. This addresses the clinical need to complement other information available." @default.
• W3136455060 created "2021-03-29" @default.
• W3136455060 creator A5002024107 @default.
• W3136455060 creator A5003148662 @default.
• W3136455060 creator A5005909669 @default.
• W3136455060 creator A5007066894 @default.
• W3136455060 creator A5008628959 @default.
• W3136455060 creator A5015777655 @default.
• W3136455060 creator A5016722505 @default.
• W3136455060 creator A5017078229 @default.
• W3136455060 creator A5022496894 @default.
• W3136455060 creator A5028923676 @default.
• W3136455060 creator A5028989065 @default.
• W3136455060 creator A5032655470 @default.
• W3136455060 creator A5033262447 @default.
• W3136455060 creator A5041159807 @default.
• W3136455060 creator A5048681494 @default.
• W3136455060 creator A5052224151 @default.
• W3136455060 creator A5054067653 @default.
• W3136455060 creator A5066298038 @default.
• W3136455060 creator A5077938334 @default.
• W3136455060 creator A5081735193 @default.
• W3136455060 creator A5085511830 @default.
• W3136455060 date "2021-04-21" @default.
• W3136455060 modified "2023-09-26" @default.
• W3136455060 title "Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients" @default.
• W3136455060 cites W1491400876 @default.
• W3136455060 cites W1549134245 @default.
• W3136455060 cites W1858021180 @default.
• W3136455060 cites W1871463035 @default.
• W3136455060 cites W1963819382 @default.
• W3136455060 cites W1964172790 @default.
• W3136455060 cites W1964864637 @default.
• W3136455060 cites W1980278159 @default.
• W3136455060 cites W1989307108 @default.
• W3136455060 cites W1992776509 @default.
• W3136455060 cites W1999578932 @default.
• W3136455060 cites W2010914453 @default.
• W3136455060 cites W2011950472 @default.
• W3136455060 cites W2017265038 @default.
• W3136455060 cites W2030985887 @default.
• W3136455060 cites W2051978340 @default.
• W3136455060 cites W2052378665 @default.
• W3136455060 cites W2052979981 @default.
• W3136455060 cites W2060209588 @default.
• W3136455060 cites W2060420666 @default.
• W3136455060 cites W2070105727 @default.
• W3136455060 cites W2073851541 @default.
• W3136455060 cites W2076511806 @default.
• W3136455060 cites W2081661793 @default.
• W3136455060 cites W2084219471 @default.
• W3136455060 cites W2084900288 @default.
• W3136455060 cites W2085319463 @default.
• W3136455060 cites W2085685321 @default.
• W3136455060 cites W2088314676 @default.
• W3136455060 cites W2097048253 @default.
• W3136455060 cites W2100143246 @default.
• W3136455060 cites W2111722073 @default.
• W3136455060 cites W2112479854 @default.
• W3136455060 cites W2118655979 @default.
• W3136455060 cites W2122146226 @default.
• W3136455060 cites W2128582098 @default.
• W3136455060 cites W2131431549 @default.
• W3136455060 cites W2135793292 @default.
• W3136455060 cites W2138897150 @default.
• W3136455060 cites W2160126594 @default.
• W3136455060 cites W2163490348 @default.
• W3136455060 cites W2165488756 @default.
• W3136455060 cites W2166500502 @default.
• W3136455060 cites W2171146053 @default.
• W3136455060 cites W2292708394 @default.
• W3136455060 cites W2323036193 @default.
• W3136455060 cites W2325213044 @default.
• W3136455060 cites W2341276226 @default.
• W3136455060 cites W2416462172 @default.
• W3136455060 cites W243098760 @default.
• W3136455060 cites W2488744181 @default.
• W3136455060 cites W2506977751 @default.
• W3136455060 cites W2513143599 @default.
• W3136455060 cites W2583565371 @default.
• W3136455060 cites W2622228475 @default.
• W3136455060 cites W2681845997 @default.
• W3136455060 cites W2747743780 @default.
• W3136455060 cites W2761810763 @default.
• W3136455060 cites W2799850385 @default.
• W3136455060 cites W2802700301 @default.
• W3136455060 cites W2811299944 @default.
• W3136455060 cites W2891569618 @default.
• W3136455060 cites W2896383683 @default.
• W3136455060 cites W2900909297 @default.
• W3136455060 cites W2916872745 @default.
• W3136455060 cites W2921445415 @default.
• W3136455060 cites W2959740191 @default.
• W3136455060 cites W2960407913 @default.
• W3136455060 cites W2977037360 @default.
• W3136455060 cites W3013026350 @default.
• W3136455060 cites W32417562 @default.
• W3136455060 cites W4361867688 @default.
• W3136455060 cites W602669826 @default.
• W3136455060 doi "https://doi.org/10.1186/s13023-021-01813-5" @default.

• next